Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Markets continue downward trend
Fri, 13 Dec 11:30 am

After opening in red, the Indian Indices continued the downward trend in the last two hours of trading session. All sectoral indices are trading in the red.

The BSE-Sensex is trading down by 160 points and NSE-Nifty is trading down by 53 points. The BSE Mid Cap index is trading down 0.51%; while the BSE Small Cap index is trading flat today. The Rupee is trading at 62.1 to the US Dollar.

Food and Tobacco stocks are trading mixed today. Golden Tobacco and Britannia are among the stocks leading the gainers. Sterling Biotech and ITC ltd are leading the losers. According to a leading financial daily, ITC Paperboards and Specialty Papers which is an arm of the ITC group wants to invest around Rs 11 bn to rev up their manufacturing capacities in the next two years at two of its plants at Bhadrachalam and Coimbatore. This division of ITC has a major part of its business coming from the packaging segment (about 75%) and the rest from papers and specialty papers. Since there is a slowdown in the packaging industry such as pharma and FMCG, ITC Paper too is facing a downward trend in its growth. Therefore, it is investing heavily in technology to cut down the production cost and making the production process efficient at its plants. ITC is trading 0.6% down today.

Indian Pharmaceutical stocks are trading mixed today. Wockhardt Ltd and Dishman Pharma are leading the gainers. Indoco Remedies and IPCA Laboratories are leading the losers. As per a press release on BSE, Cadila Healthcare Ltd. has settled a patent litigation with US-based Warner Chilcott Company LLC. Cadila and its US subsidiary- Zydus Pharmaceuticals (USA) Inc have entered into an agreement with Warner Chilcott to settle all outstanding patent litigation related to Asacol HD (a brand name of mesalamine) delayed-release tablets. This drug is used to treat ulcerative colitis that affects any part of the colon. As per the terms of the agreement, Warner Chilcott shall give Cadila and Zydus a royalty-bearing license to market a generic version of its patented drug Asacol HD from November 15, 2015 or earlier. The license shall be granted after Zydus gets the nod from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for generic version of Asacol HD. Also, if Zydus does not receive USFDA approval of its generic version of Asacol HD by July 1, 2016, Zydus will be permitted to launch an authorized generic version of Asacol HD from July 1, 2016 onwards. However, any other terms of the settlement were not disclosed. Cadila is trading flat today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets continue downward trend". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.